Price$1.99-0.31 (-13.70%)
2026-01-262026-04-29
News · 26 weeks41-43%
2025-11-022026-04-26
Mix1790d
- SEC Filings9(53%)
- Other5(29%)
- Insider2(12%)
- Earnings1(6%)
Latest news
25 items- SECSEC Form 10-Q filed by Vicarious Surgical Inc.10-Q - Vicarious Surgical Inc. (0001812173) (Filer)
- PRVicarious Surgical Reports First Quarter 2026 Financial ResultsWALTHAM, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (OTCQB:RBOT), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Results Total operating expenses were $7.5 million in the first quarter of 2026, compared to $15.7 million in the first quarter of 2025, a decrease of 52%. Research and development expenses in the first quarter of 2026 were $5.0 million, compared to $9.4 million in the first quarter of 2025, a decrease of 46%. General and administrative expenses in the
- SECVicarious Surgical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Vicarious Surgical Inc. (0001812173) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Vicarious Surgical Inc.SCHEDULE 13D/A - Vicarious Surgical Inc. (0001812173) (Subject)
- PRVicarious Surgical Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia RepairWALTHAM, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB:RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the "Company"), today announced the successful completion of initial integrated benchtop testing for its full suite of surgical instruments, required for its anticipated first clinical indication of ventral hernia repair, marking an important step toward design validation, clinical readiness, and the Company's targeted design freeze milestone. This milestone represents the first system-level performance evaluation of the Company's three core instruments: needle drivers, fenestrated graspers, and monopolar sc
- PRVicarious Surgical Begins Quotation on the OTCQB as Part of Strategic Path Toward Potential Nasdaq ListingWALTHAM, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB:RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the "Company"), today announced that it has received approval for its Class A common stock to upgrade to the OTCQB® Venture Market by OTC Markets Group Inc. (the "OTCQB"). The Company's Class A common stock has begun quotation on the OTCQB as of March 24, 2026, under the ticker symbol RBOT. This milestone represents a key step in the Company's broader capital markets strategy as it advances toward a potential listing on the Nasdaq Capital Market. The OTCQB is designed for early-stage and developing companies
- SECSEC Form DEF 14A filed by Vicarious Surgical Inc.DEF 14A - Vicarious Surgical Inc. (0001812173) (Filer)
- SECSEC Form 25-NSE filed by Vicarious Surgical Inc.25-NSE - Vicarious Surgical Inc. (0001812173) (Subject)
- SECSEC Form PRE 14A filed by Vicarious Surgical Inc.PRE 14A - Vicarious Surgical Inc. (0001812173) (Filer)
- SECVicarious Surgical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Vicarious Surgical Inc. (0001812173) (Filer)
- SECSEC Form 10-K filed by Vicarious Surgical Inc.10-K - Vicarious Surgical Inc. (0001812173) (Filer)
- SECVicarious Surgical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Vicarious Surgical Inc. (0001812173) (Filer)
- SECVicarious Surgical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - Vicarious Surgical Inc. (0001812173) (Filer)
- PRVicarious Surgical Receives Delisting Notice From NYSEVicarious Surgical Inc. (NYSE:RBOT) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that on March 3, 2026, it received a notice (the "Notice") from the New York Stock Exchange (the "NYSE") that the NYSE has commenced the process of delisting the Company's Class A common stock, par value $0.0001 per share (the "Common Stock"). Trading on the Company's Common Stock on the NYSE was suspended after market close on March 3, 2026. The NYSE has determined that the Company has fallen below the continued listing standard, requiring listed companies to maintain an average global market capitalization over a con
- INSIDERPresident Sachs Adam David sold $1,967 worth of shares (942 units at $2.09), decreasing direct ownership by 2% to 46,943 units (SEC Form 4)4 - Vicarious Surgical Inc. (0001812173) (Issuer)
- INSIDERChief Technology Officer Khalifa Sammy sold $1,571 worth of shares (754 units at $2.08), decreasing direct ownership by 2% to 32,869 units (SEC Form 4)4 - Vicarious Surgical Inc. (0001812173) (Issuer)
- SECVicarious Surgical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Vicarious Surgical Inc. (0001812173) (Filer)
- PRVicarious Surgical Advances Toward Design Freeze with Successful In-Vivo Porcine LabVicarious Surgical (NYSE:RBOT) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the successful completion of an in-vivo porcine lab conducted in December 2025, marking a meaningful step forward in the development of the company's robotic system and reinforcing progress toward system design freeze targeted for the end of 2026. During the lab, surgeons independently completed key elements of a ventral hernia repair using Vicarious Surgical's pre-DV system as part of a limited-scope feasibility assessment. In parallel, the company executed a series of targeted technical evaluations designed to assess syst
- SECVicarious Surgical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Vicarious Surgical Inc. (0001812173) (Filer)
- PRVicarious Surgical Announces Strategic Software Execution Partnership to Streamline OperationsVicarious Surgical Inc. (NYSE:RBOT) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that it has entered into a strategic partnership agreement with a global digital engineering and software development services firm. This engagement is a central component of the Company's broader operating model transformation, designed to improve execution, increase development predictability, and reduce operating expenses as reflected in the Company's cash burn guidance, through a more efficient mix of internal and external engineering resources. Under the agreement, the external engineering partner will assume resp
- SECSEC Form EFFECT filed by Vicarious Surgical Inc.EFFECT - Vicarious Surgical Inc. (0001812173) (Filer)
- SECSEC Form 424B5 filed by Vicarious Surgical Inc.424B5 - Vicarious Surgical Inc. (0001812173) (Filer)
- SECSEC Form 25-NSE filed by Vicarious Surgical Inc.25-NSE - Vicarious Surgical Inc. (0001812173) (Subject)
- SECVicarious Surgical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits8-K - Vicarious Surgical Inc. (0001812173) (Filer)
- PRVicarious Surgical Announces Full Year 2026 Cash Burn GuidanceVicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced its full-year 2026 cash burn guidance. Vicarious Surgical expects full-year 2026 cash burn of approximately $35 million, representing a $10 million improvement from the Company's recently updated 2025 guidance of $45 million. Cash needs beyond existing cash resources to achieve design freeze on the Vicarious Surgical system are approximately $25 million. The improved guidance reflects a strong continuation of the Company's operational reset. Key drivers include reductions in headcount and external consulting s
RBOT FAQ
7 questionsWhat does Vicarious Surgical Inc. do?
Vicarious Surgical Inc. operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Where does RBOT stock trade?
Vicarious Surgical Inc. (RBOT) is listed on NYSE.What sector and industry is RBOT in?
Vicarious Surgical Inc. operates in the Health Care sector, Industrial Specialties industry.When did Vicarious Surgical Inc. go public?
Vicarious Surgical Inc. (RBOT) completed its IPO in 2020.What are analysts saying about RBOT?
Vicarious Surgical Inc. has had 6 recent analyst actions on file. The most recent action was from Piper Sandler: Neutral with a $700.00 price target on 2022-03-04. Recent price targets range from $700.00 to $1600.00.What companies are similar to RBOT?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare RBOT side-by-side with any of them on Quantisnow.How can I track RBOT on Quantisnow?
Quantisnow aggregates Vicarious Surgical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RBOT to receive live email and push alerts on every new disclosure.